Study directly compares Zepbound and Wegovy for weight-loss results

Study directly compares Zepbound and Wegovy for weight-loss results

Researchers find tirzepatide leads to greater reduction in body weight and waist size

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide (brand name Wegovy) in a 72-week clinical trial. (iStock)

The randomized, controlled trial — called SURMOUNT-5 — included 751 people in the U.S. and Puerto Rico who had obesity but not type 2 diabetes. (Steve Christo – Corbis/Corbis via Getty Images)

The study found that tirzepatide achieved greater weight loss, with participants shedding about 50 pounds (20.2% of their body weight). (iStock)

Beyond weight loss, semaglutide has also shown potential benefits for cardiovascular health, sleep apnea and kidney disease. (iStock)

An expert emphasized that people should work with a physician to choose a weight-loss medication that matches personal goals and health status. (iStock)

"Across the respective clinical trial programs and in SURMOUNT-5, both Wegovy and Zepbound have demonstrated clinically significant weight reduction," Novo Nordisk, maker of Wegovy, said in a statement. (iStock)